NexTel Medical to Acquire Xycota Biosciences, Gaining Exosome-Delivered Neuro-Restoration Platform with Pending FDA Orphan Drug Designation
核心洞察
NexTel Medical Corp. (搜索) has executed a definitive Letter of Intent to acquire 100% of preclinical biotech Xycota Biosciences, LLC (搜索).
Xycota's lead candidate XYCO-01 (搜索) uses fungal-derived exosomes to upregulate the BDNF-TrkB (搜索) pathway for brain circuitry repair without psychedelic side effects.
Xycota has applied for FDA Orphan Drug Designation for XYCO-01 (搜索) in Frontotemporal Dementia (搜索), which would provide seven years of U.S. market exclusivity upon approval.
NexTel Medical Corp. (搜索) (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) announced on August 5, 2026 that it has executed a definitive Letter of Intent to acquire 100% of Xycota Biosciences, LLC (搜索), a preclinical biotechnology company developing precision-targeted therapeutics designed to physically repair brain circuitry and restore synaptic connectivity in neurodegenerative diseases.
The acquisition positions NexTel at the forefront of what the company describes as precision neuro-restoration, leveraging Xycota's proprietary exosome-delivered platform to address conditions where no restorative therapies currently exist.
Platform Mechanism and Lead Candidate
Xycota's lead candidate, XYCO-01 (搜索), employs proprietary fungal-derived exosome delivery systems to directly upregulate the BDNF-TrkB (搜索) neuroplasticity signaling pathway. Critically, the therapeutic bypasses first-pass liver metabolism and avoids hallucinogenic receptor activation, decoupling neural restoration from psychedelic side effects. This approach establishes what the company characterizes as a standardized, controllable mechanism for structural brain repair.
The platform's scientific foundation is anchored by peer-reviewed mechanistic evidence published in the Nature Portfolio journal Neuropsychopharmacology (Trezza, Hausman, et al., 2026), which demonstrated that synaptic restoration and cognitive improvement can be achieved by modulating intrinsic BDNF/TrkB growth pathways.
Regulatory Milestone: Pending Orphan Drug Designation
Xycota has formally applied for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration for XYCO-01 (搜索) in its primary indication, Frontotemporal Dementia (搜索) (FTD). The company stated that official issuance of the ODD status is expected shortly. Upon designation and approval, ODD status would provide seven years of U.S. market exclusivity, tax credits for qualified clinical testing, and regulatory fee exemptions.
Pipeline Expansion Potential
While Frontotemporal Dementia (搜索) serves as the initial lead indication, Xycota's platform offers a pathway for rapid expansion into Amyotrophic Lateral Sclerosis (搜索) (ALS), mild traumatic brain injury (搜索) (mTBI), and broader neurodegenerative conditions — all areas with significant unmet clinical need.
Leadership and Expertise
Xycota's pipeline is led by Co-Founder and Chief Scientific Officer Dr. Marvin S. Hausman, MD, who brings over 50 years of CNS drug development experience, six successful FDA NDAs, and a proven track record of commercial exits.
"Executing this LOI to acquire 100% of Xycota Biosciences marks a defining milestone in NexTel Medical's corporate development and growth trajectory," said Matthew Dwyer, President and Chief Executive Officer of NexTel Medical Corp. (搜索) "Xycota's cutting-edge exosome delivery platform addresses immense unmet clinical needs in Frontotemporal Dementia (搜索) and ALS where no restorative therapies currently exist. Combining Xycota's breakthrough neuro-restoration architecture with NexTel's commercial infrastructure creates an extraordinary, value-generative catalyst for our shareholders."